|
|
||||||||
Published online before print May 30, 2008
| ||||||||||||||||||||||||||||||||||||||||||||||||||||


* Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; and
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA
2 Correspondence: Cancer Immunology Program, Peter MacCallum Cancer Centre, Locked Bag 1, ABeckett St., 8006, Victoria, Australia. E-mail: mark.smyth{at}petermac.org
ABSTRACT
This brief review discusses the role of the immune system in tumor development, covering a history of cancer immunity and a summary of the concept of cancer immunoediting, including its three phases: elimination, equilibrium, and escape. The latter half of this review then focuses specifically on the equilibrium phase, making note of previous work, suggesting that immunity might maintain cancer in a dormant state, and concluding with a description of a tractable mouse model unequivocally demonstrating that immunity can indeed hold preformed cancer in check. These findings form a framework for future studies aimed at validating immune-mediated cancer dormancy in humans with the hopes of devising new, immunotherapeutic strategies to treat established cancer.
Key Words: immunoediting elimination escape
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |